Slingshot members are tracking this event:

Agios (AGIO) Announces Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Management Comment “Many newly diagnosed AML patients cannot tolerate intensive chemotherapy, which limits their available treatment options,” said Anthony S. Stein, M.D., study investigator and co-director of the leukemia program at City of Hope Cancer Center. “Based on the safety and efficacy demonstrated in clinical studies of AG-221 and AG-120 in relapsed / refractory AML, there is potential to provide a new treatment option for newly diagnosed IDH mutant AML patients by combining these therapies with VIDAZA® in the frontline setting.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 30, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Ag-221, Ag-120, Vidaza, Acute Myeloid Leukemia, Drug Combinations